-
Mashup Score: 7
Medications are foundational to the provision of healthcare. At the same time, they have significant environmental impacts. Medications are estimated to cont…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Getting the Math Right: The Growing Movement to Improve How Medicines Are Valued Will Take Center Stage at ISPOR 2024 - 6 month(s) ago
Health Economists and Policy Experts to Highlight Rationale for and Implementation of Generalized Cost-Effectiveness AnalysisATLANTA, May 03, 2024 (GLOBE NEWSWIRE) — Leading health economists will gather in Atlanta on May 5-8 for a meeting of the Professional Society for Health Economics and Outcomes Research (ISPOR), where a growing number of experts will make the case for updating the cost-effectiveness methodology conventionally used by health plans and foreign governments to determine wheth
Source: finance.yahoo.comCategories: General Medicine News, Hem/OncsTweet-
This press release provides detail on presentations related to generalized CEA at #ISPORAnnual next week. Attendees should note that there are MAJOR issues with #GCEA. It does not represent best practices in CEA nor does it align with the goals of CEA. https://t.co/2uif1fX6C2
-
-
Mashup Score: 1Climate Change and Mental Health - 6 month(s) ago
This JAMA Insights discusses the adverse effects of climate change on mental health and proposes solutions to help mitigate those effects.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
'Further scientific investigation is needed to more clearly delineate the effects of #climatechange on #mentalhealth as well as the factors that influence who experiences these effects...' by @sdclaytonphd & L Brown via @JAMA_current 🌎 https://t.co/D3hL6EywVF
-
-
Mashup Score: 4The top 20 pharma companies by 2023 revenue - 7 month(s) ago
There were changes at the top and the bottom of last year’s top 20 pharma rankings by revenue. And, in between, Novo Nordisk made a significant leap, jumping five spots propelled by skyrocketing sales of its diabetes and obesity treatments Ozempic and Wegovy. Accounting for the changes at the high and low ends of the rankings were plummeting sales of COVID-19 products. | 2023 was all about diabetes and obesity drug sellers Novo Nordisk and Eli Lilly posting huge revenue gains as they were the only companies in the biopharma industry with double-digit gains. At the other end of the spectrum, sellers of COVID products saw dramatic decreases in revenue as Pfizer, the top revenue drugmaker in 2022, had a 41% decrease, while Moderna and BioNTech tumbled out of the top 20.
Source: www.fiercepharma.comCategories: General Medicine News, Hem/OncsTweet-
"Novo and Lilly were the only drugmakers in the top 20 with double-digit revenue increases, demonstrating the remarkable impact weight loss drugs have had on the market." via @KDunleavy / @FiercePharma https://t.co/EGkjpp3ERu
-
-
Mashup Score: 2Home - 7 month(s) ago
29 November 2023
Source: sites.google.comCategories: General Medicine News, Hem/OncsTweet-
🌎New post! 🌎 Featuring new research by @HensherMartin on the complexities of degrowth & healthcare. Also, work published in @JAMAOnc from researchers at @radboudumc on promoting environmental/financial sustainability by redispensing anticancer drugs. https://t.co/txeftrrMKI https://t.co/6psHDjnmHe
-
-
Mashup Score: 4The top 20 pharma companies by 2023 revenue - 7 month(s) ago
There were changes at the top and the bottom of last year’s top 20 pharma rankings by revenue. And, in between, Novo Nordisk made a significant leap, jumping five spots propelled by skyrocketing sales of its diabetes and obesity treatments Ozempic and Wegovy. Accounting for the changes at the high and low ends of the rankings were plummeting sales of COVID-19 products. | 2023 was all about diabetes and obesity drug sellers Novo Nordisk and Eli Lilly posting huge revenue gains as they were the only companies in the biopharma industry with double-digit gains. At the other end of the spectrum, sellers of COVID products saw dramatic decreases in revenue as Pfizer, the top revenue drugmaker in 2022, had a 41% decrease, while Moderna and BioNTech tumbled out of the top 20.
Source: www.fiercepharma.comCategories: General Medicine News, Hem/OncsTweet-
"Novo and Lilly were the only drugmakers in the top 20 with double-digit revenue increases, demonstrating the remarkable impact weight loss drugs have had on the market." via @KDunleavy / @FiercePharma https://t.co/EGkjpp3ERu
-
-
Mashup Score: 2Climate change and healthcare - 17 April 2024 - 7 month(s) ago
A post on LinkedIn led me to this ‘Environmental Impacts’ collection of articles published in the journal Applied Health Economics and Health Policy. At present, it only has a few articles but provides a nice starting point for new articles at the intersection of health economics/policy and
Source: sites.google.comCategories: General Medicine News, Hem/OncsTweet-
New post!🌎 This week: highlighting a collection of articles about health economics & the environment in @ApplHealthEcon. Also, in @BMJ_Open, a qualitative study led by @DrNicoleRedvers on physicians' views on patient-planetary health co-prescribing. https://t.co/izqlEH9udN
-
-
Mashup Score: 10Jobs - The University of York - 7 month(s) ago
The Centre for Health Economics (CHE) at the University of York is seeking to appoint a Research Fellow within the Health Policy team on a full-time open contract (part-time applications will also be considered with a minimum of 0.8 FTE). The successful applicant will contribute to our existing portfolio of research projects, applying an economic perspective to the quantitative analysis and evaluation of health, social and mental health policy at the intersection of demand for and supply of health and
Source: jobs.york.ac.ukCategories: General Medicine News, Hem/OncsTweet-
RT @CHEyork: We're looking to appoint a Research Fellow to our Health Policy Team. Further details at https://t.co/5eGdvkAiwf. https://t.co…
-
-
Mashup Score: 3Home - 8 month(s) ago
29 November 2023
Source: sites.google.comCategories: General Medicine News, Hem/OncsTweet-
🌎New post! 🌎 Featuring new research by @HensherMartin on the complexities of degrowth & healthcare. Also, work published in @JAMAOnc from researchers at @radboudumc on promoting environmental/financial sustainability by redispensing anticancer drugs. https://t.co/txeftrrMKI https://t.co/6psHDjnmHe
-
-
Mashup Score: 2Cost-effectiveness of the top 100 drugs by public spending in Canada, 2015–2021: a repeated cross-sectional study - 8 month(s) ago
Objectives To assess the distribution and spending by cost-effectiveness category among those drugs with the highest public spending levels in Canada. Design Repeated cross-sectional study. Setting The Canadian provinces of Manitoba, Ontario, New Brunswick, Nova Scotia, Prince Edward Island and Newfoundland. Main outcomes and measures Cost-effectiveness assessments by the Canadian Agency for Drugs and Technologies in Health (CADTH) for top-100 brand-name outpatient drugs by gross public plan spending in any year between 2015 and 2021 in Canada Institute for Health Information’s National Prescription Drug Utilization Information System data. Gross public plan spending by cost-effectiveness category. Results From 2015 to 2021, 152 brand-name drugs occupied a top-100 rank and were included in the analysis. Of those, 117 had been assessed by CADTH. During the 7-year period, there was an increase in both top-100 drugs with cost-effective (from 18 to 24) and cost-ineffective (from 29 to 41)
Source: bmjopen.bmj.comCategories: General Medicine News, Hem/OncsTweet-
Really interesting! '.. some cost-ineffective drugs may provide.. treatment options to patients, allocating large budgets to such treatments prevents spending with greater health impact elsewhere in the healthcare system' by @Mina_T et al (@UofTPharmacy) https://t.co/2sSZ9Pg0H9
-
Interested in medications and climate change? 🌎 Check out this great seminar by Ivy Lam, @IlonaHale, and Trudy Huyghebaert organized by @cascades_en! https://t.co/LRKTOpPirR